Arix Bioscience is a global healthcare and life science company that drives value in private and public companies through operational and strategic direction as well as patient capital
Led by renowned figures in the healthcare and life science sectors, Arix Bioscience is headquartered in London and has an office in New York.
Our extensive experience in academic science, clinical and commercial strategy, company operations, mergers and acquisitions, venture capital and corporate finance puts us in an especially strong position to build and support a wide range of businesses and technologies.
Arix Bioscience has privileged agreements with leading universities in the UK, Europe and Australia, providing direct access to innovative new technologies. We also have access to a broad range of research projects from US academic institutions.
Introduction to Arix Bioscience
Fund Management Business
Arthurian Life Sciences Ltd (ALS) is a wholly-owned subsidiary of Arix Bioscience plc and operates as the regulated investment manager of the Group. ALS is also the Manager of The Wales Life Sciences Investment Fund (WLSIF) and is authorised and regulated by the Financial Conduct Authority.
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. Arix has a strategic agreement to provide to UCB reasonable access to its process of investing in its Group Businesses, including participation in sourcing, screening, due diligence and joint business building with a view to facilitating UCB’s participation in such Group Businesses. The focus of the strategic partnership is in immunology, neurology and bone and managed through a joint advisory committee.
Takeda is a global research and development-driven pharmaceutical company translating science into life-changing medicines. Arix has a strategic agreement to provide to Takeda reasonable access to its process of investing in its Group Businesses, including participation in sourcing, screening, due diligence and joint business building with a view to facilitating Takeda’s participation in such Group Businesses. The focus of the strategic partnership is in oncology and gastrointestinology and managed through a joint advisory committee.